NANO — Nanobiotix SA Share News
0.000.00%
Last trade - 00:00- €971.36m
- €967.08m
- €7.84m
Brief: Nanobiotix Executes Definitive Agreement To Restructure Existing Loan With The European Investment Bank
Brief: Nanobiotix SA H1 Net Loss At EUR 26.4 Mln
Brief: Nanobiotix Establishes Recommended Dose For Planned Registrational Study Evaluating NBTXR3 Plus ANTI-PD-1
Brief: Nanobiotix: Agreement Restructure Existing Loan Agreement With European Investment Bank
Brief: Nanobiotix And Lianbio Announce First Patient Enrolled In Asia In Phase 3 Nanoray-312 Trial Evaluating Nbtxr3 For Treatment Of Head And Neck Cancer
Brief: Nanobiotix Announces New NBTXR3 Data In Oncology
Brief: Nanobiotix Sees Available Capital Funding Operations Into Q4 2023 At Least
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:23 PM
Brief: Nanobiotix Says New Preclinical Data Show Boosted Anti-Tumor Immune Activation
Europe Research Roundup: AJ Bell, Euronext, LSE
Brief: Nanobiotix FY Net Loss Widens To EUR 47 Mln
Brief: Nanobiotix Publishes New Clinical Case Study For Pancreatic Cancer Treatment
Brief: Nanobiotix Announces Publication Of New Preclinical Immunotherapy Data
Brief: Nanobiotix End-Dec Estimated Cash Position At Around EUR 83.9 Mln
Brief: Nanobiotix Announces 18.1 Month Median Overall Survival For 41 Evaluable Elderly, Frail Patients With HNSCC In Phase I Expansion Evaluating Nbtxr3
Brief: Nanobiotix Announces Red Journal Publication Of Preclinical Data Showing Radioenhancer NBTXR3 May “Reprogram” The Tumor Microenvironment To Overcome Anti-PD-1 Resistance And Evoke Abscopal Effect
Europe Research Roundup: BMW, Ferrari, HSBC
Brief: Nanobiotix H1 Net Loss Attributable To Common Shareholders Widens To EUR 30.4 Mln
Brief: Nanobiotix H1 Total Revenue Down At 9,700 Euros